Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology

British Journal of Haematology

Volumn 169, Issue 5, 2015, Pages 661-671

  Jones, Gail L ^a   Will, Andrew ^b   Jackson, Graham H ^a   Webb, Nicholas J A ^b   Rule, Simon ^c   on Behalf of the British Committee for Standards in Haematology, ^d  

^a FREEMAN HOSPITAL   (United Kingdom)

^b ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^c DERRIFORD HOSPITAL   (United Kingdom)

^d British Society for Haematology   (United Kingdom)

Author keywords

Chemotherapy; Clinical haematology; Haematological malignancy; Haematological oncology; Tumour lysis syndrome

Indexed keywords

ALLOPURINOL; GLUCONATE CALCIUM; POTASSIUM; RASBURICASE; ANTINEOPLASTIC AGENT;

ADULT; ALKALINIZATION; ARTICLE; CHILD; DRUG ANTAGONISM; DRUG MECHANISM; FLUID BALANCE; FLUID THERAPY; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERURICEMIA; HYPOCALCEMIA; LOW RISK PATIENT; MEDICAL SOCIETY; META ANALYSIS (TOPIC); PATHOPHYSIOLOGY; PATIENT MONITORING; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; RISK FACTOR; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TUMOR LYSIS SYNDROME; COMPLICATION; DISEASE MANAGEMENT; HEMATOLOGIC NEOPLASMS;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DISEASE MANAGEMENT; HEMATOLOGIC NEOPLASMS; HUMANS; RISK FACTORS; TUMOR LYSIS SYNDROME;

EID: 84929272262     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13403     Document Type: Article

References (48)

1. Alkhuja, S. & Ulrick, H. (2002) Acute renal failure from spontaneous tumor lysis syndrome: a case report and review. Renal Failure, 24, 227-232.
2. Annemans, L., Moeremans, K., Lamotte, M., Garcia Conde, J., van den Berg, H., Myint, H., Pieters, R. & Vyttebroeck, A. (2003) Incidence, medical resource utilisation and costs of hyperuricaemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin lymphoma in four European countries. Leukaemia and Lymphoma, 44, 77-83.
3. Bedrna, J. & Polcák, J. (1929) Akutar Harnleiterverschluss nach Bertrahlung chronischer Leukämien mit Röntgenstrahlen. Medizinische Klinik, 25, 1700-1701.
4. de Bont, J.M. & Pieters, R. (2004) Management of hyperuricaemia with rasburicase review. Nucleosides, Nucleotides & Nucleic Acids, 23, 1431-1440.
5. Bosly, A., Sonet, A., Pinkerton, C.R., McCowage, G., Bron, D., Sanz, M.A. & Van den Berg, H. (2003) Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer. Cancer, 98, 1048-1054.
6. Brogard, J.M., Coumaros, D., Franckhauser, J., Stahl, A. & Stahl, J. (1972) Enzymatic uricolysis: a study of the effect of a fungal uric oxidase. Revues Europeenne d' Etudes Cliniques et Bioliologiques, 17, 890-895.
7. Cairo, M.S. & Bishop, M. (2004) Tumour lysis syndrome: new therapeutic strategies and classification. British Journal Haematology, 127, 3-11.
8. Cairo, M.S., Coiffier, B., Reiter, A. & Younes, A. (2010) Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. British Journal of Haematology, 149, 578-586.
9. Candrilli, S., Bell, T., Irish, W., Morris, E., Godman, S. & Cairo, M.S. (2008) A comparison of inpatient length of stay and costs among patients with haematologic malignancies (excluding Hodgkin disease) associated with and without acute renal failure. Clinical Lymphoma and Myeloma, 8, 44-51.
10. Coiffier, B., Mounier, N., Bologna, S., Fermé, C., Tilly, H., Sonet, A., Christian, B., Casasnovas, O., Jourdan, E., Belhadj, K. & Herbrecht, R. & Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma. (2003) Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. Journal of Clinical Oncology, 21, 4402-4406.
11. Coiffier, B., Altman, A., Pui, C.-H., Younes, A. & Cairo, M.S. (2008) Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. Journal of Clinical Oncology, 26, 2767-2778.
12. Coutinho, A.K., de O Santos, M., Pinczowski, H., Feher, O. & del Giglio, A. (1997) Tumor lysis syndrome in a case of chronic lymphocytic leukemia induced by high-dose corticosteroids. American Journal of Hematology, 54, 85-86.
13. Coutsouvelis, J., Wiseman, M., Hui, L., Poole, S., Dooley, M., Patil, S., Avery, S., Wei, A. & Spencer, A. (2012) Effectiveness of a single fixed dose of rasburicase 3 mg in the management of tumour lysis syndrome. British Journal of Clinical Pharmacology, 75, 550-553.
14. Darmon, M., Vincent, F., Camous, L., Canet, E., Bonmati, C., Braun, T., Caillot, D., Cornillon, J., Dimicoli, S., Etienne, A., Galicier, L., Garnier, A., Girault, S., Hunault-Berger, M., Marolleau, J.-P., Moreau, P., Raffoux, E., Recher, C., Thiebaud, A., Thieblemont, C. & Azoulay, E. and the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique (GRRR-OH) (2013), Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique. British Journal of Haematology, 162, 489-497.
15. Davidson, M.B., Thakker, S., Hix, J.K., Bhandarker, N.D., Wong, A. & Schrieber, M.J. (2004) Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. American Journal of Medicine, 116, 546-554.
16. Deger, G.E. & Wagoner, R.D. (1972) Peritoneal dialysis in acute uric acid nephropathy. Mayo Clinic Proceedings, 47, 189-192.
17. Feng, X., Dong, K., Pham, D., Pence, S., Inciardi, J. & Bhutada, N.S. (2013) Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis. Journal of Clinical Pharmacy and Therapeutics, 38, 301-308.
18. Flombaum, C.D. (2000) Metabolic emergencies in the cancer patient. Seminars in Oncology, 27, 322-334.
19. Galardy, P.J., Hochberg, J., Perkins, S.I., Harrison, L., Goldman, S. & Cairo, M.S. (2013) Rasburicase in the prevention of laboratory/clinical tumour lysis sydrome in children with advanced mature B-NHL: a Children's Oncology Group Report. British Journal Haematology, 163, 365-372.
20. Goldman, S.C., Holcenberg, J.S., Finklestein, J.Z., Hutchinson, R., Kreissman, S., Johnson, F.L., Tou, C., Harvey, E., Morris, E. & Cairo, M.S. (2001) A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood, 97, 2998-3003.
21. Hande, K.R., Hixson, C.V. & Chabner, B.A. (1981) Post-chemotherapy purine excretion in lymphoma patients receiving allopurinol. Cancer Research, 41, 2273-2279.
22. Howard, S.C., Jones, D.P. & Pui, C.-H. (2011) The tumor lysis syndrome. New England Journal of Medicine, 364, 1844-1854.
23. Hsu, H.H., Chan, Y.L. & Huang, C.C. (2004) Acute spontaneous tumor lysis syndrome presenting with hyperuricemic renal failure: clinical features and therapeutic approach. Journal of Nephrology, 17, 50-56.
24. Jasek, A.M. & Day, H.J. (1994) Acute spontaneous tumor lysis syndrome. American Journal of Hematology, 47, 129-131.
25. TM), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia, 19, 34-38.
26. Jones, D.P., Mahmoud, H. & Chesney, R.W. (1995) Tumor lysis syndrome pathophysiology and management. Pediatric Nephrology, 9, 206-212.
27. Locatelli, F. & Rossi, F. (2005) Incidence and pathogenesis of tumor lysis syndrome. Contributions to Nephrology, 147, 61-68.
28. Matthey, F., Parker, A., Rule, S.A.J., Wimperis, J.Z., Ardeshna, K.M., Bird, J.M., Cullis, J., Lyttelton, M.P.A., McMillan, A. & Jackson, G.H. (2010) Facilities for the treatment of adults with haematological malignancies - 'levels of care'. BCSH haemato-oncology task force 2009. Hematology, 15, 63-69.
29. Moreau, D. (2005) Pharmacological treatment of acute renal failure in intensive care patients. Contributions to Nephrology, 147, 161-173.
30. Pieters, R. & Uyttebroeck, A. (2003) Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Supportive Care in Cancer, 11, 249-257.
31. Pui, C.-H. (2002) Rasburicase: a potent uricolytic agent. Expert Opinion in Pharmacotherapy, 3, 433-452.
32. Pui, C.-H., Mahmoud, H.H., Wiley, J.M., Woods, G.M., Leverger, G., Camitta, B., Hastings, C., Blaney, S.M., Relling, M.V. & Reaman, G.H. (2001) Recombinant urate oxidase for the prophylaxis or treatment of hyperuricaemia in patients with leukaemia or lymphoma. Journal of Clinical Oncology, 19, 697-704.
33. Rampello, E., Fricia, T. & Malaguarnera, M. (2006) The management of tumor lysis syndrome. Nature, Clinical Practice Oncology, 3, 438-447.
34. Ribiero, R.C. & Pui, H.-C. (2003) Recombinant urate oxidase for the prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies. Clinical Lymphoma, 3, 225-232.
35. Sallan, S. (2001) Management of acute tumor lysis síndrome. Seminars in Oncology, 28, S9-S12.
36. Sparano, J., Ramirez, M. & Wiernik, P.H. (1990) Increasing recognition of corticosteroid-induced tumor lysis syndrome in non-Hodgkin's lymphoma. Cancer, 65, 1072-1073.
37. Ten Harkel, A.D., Kist-Van Holthe, J.E., Van Weel, M. & Van der Vorst, M.M. (1998) Alkalinization and the tumor lysis syndrome. Medical and Pediatric Oncology, 31, 27-28.
38. Tosi, P., Barosi, G., Lazarro, C., Liso, V., Marchetti, M., Morra, E., Pession, A., Rosti, G., Santoro, A., Zinzani, P. L. & Tura, S. (2008) Consensus conference on the management of tumor lysis syndrome. Haematologica, 93, 1877-1885.
39. Trifilio, S., Gordon, L., Singhal, S., Tallman, M., Evens, A., Rashid, K., Fishman, M., Masino, K., Pi, J. & Mehta, J. (2006) Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplantation, 37, 997-1001.
40. Trifilio, S.M., Pi, J., Zook, J., Golf, M., Coyle, K., Greenberg, D., Newman, D., Koslosky, M. & Mehta, J. (2011) Effectiveness of a singe 3-mg rasburicase dose for the management of hyperuricemia in patients with haematological malignancies. Bone Marrow Transplantation, 46, 800-805.
41. Vadhan-Raj, S., Fayad, L.E., Fanale, M.A., Pro, B., Rodriguez, A., Hagemeister, F.B., Buesco-Ramos, C.E., Zhou, X., McLaughkin, P.N., Fowler, N., Shah, J., Orlowski, R.Z., Samaniego, F., Wang, M., Cortes, J.E., Younes, A., Kwak, L.W., Sarlis, N.J. & Romaguera, J.E. (2012) A randomised trial of single-dose rasburicase versus five-daily doses for patients at risk of tumor lysis syndrome. Annals of Oncology, 23, 1640-1645.
42. Van den Berg, H. & Reintsema, A.M. (2004) Renal tubular damage in rasburicase: risks of alkalinisation. Annals of Oncology, 15, 175-176.
43. Will, A. & Tholouli, E. (2011) The clinical management of tumour lysis syndrome in haematological malignancies. British Journal of Haematology, 154, 3-13.
44. Wössman, W., Schrappe, M., Meyer, U., Zimmermann, M. & Reiter, A. (2003) Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Annals of Hematology, 82, 160-165.
45. Yamazaki, H., Hanada, M., Horiki, M., Kuyama, J., Sato, T., Nishikubo, M., Ishida, T. & Inoue, T. (2004) Acute tumor lysis syndrome caused by palliative radiotherapy in patients with diffuse large B-cell lymphoma. Radiation Medicine, 22, 52-55.
46. Yang, H., Rosove, M.H. & Figlin, R.A. (1999) Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. American Journal of Hematology, 62, 247-250.
47. Yelandi, A.V., Yelandi, Y., Kumar, S., Murthy, C.V., Wang, X.D., Alvares, K., Rao, M.S. & Roddy, J.K. (1991) Molecular evolution of the urate oxidase-encoding gene in hominoid primates: nonsense mutations. Gene, 109, 281-284.
48. Yim, B.T., Sims-McCallum, R.P. & Chong, P.H. (2003) Rasburicase for the treatment and prevention of hyperuricemia. The Annals of Pharmacotherapy, 37, 1047-1054.